Singapore startup Mesh Bio has raised $3.5 million in a Series A funding round led by East Ventures. Elev8, Seed Capitals and other shareholders also participated in the round.
What is it for?
The company said in a statement that it will use the new funding to expand the rollout of its solutions, particularly its flagship digital twin product, in Hong Kong and across Southeast Asia.
In 2019, the World Health Organization found that 76% of deaths in the region were due to non-communicable diseases such as heart disease and diabetes. Mesh Bio focuses on Indonesia and the Philippines, both countries where chronic diseases are said to be the most prevalent and deadly. CEO and co-founder Dr. Andrew Wu said, “There are countless unmet medical needs in Southeast Asia, and our company is focused on effectively addressing these gaps.” Stated.
bigger trends
The latest funding comes three months after Mesh Bio received regulatory approval from the Singapore Health Sciences Authority for HealthVector Diabetes. Digital twin-based software as a medical device can predict a type 2 diabetic patient's 3-year risk of developing chronic kidney disease using clinical data obtained from the hospital's EMR.
The digital twin solution is an extension of Mesh Bio's DARA Health Intelligence Platform and is currently being trialled at Singapore General Hospital, Tan Tock Seng Hospital, and select general hospitals in Singapore.
The development of HealthVector Diabetes It was first reported in October.
